bortezomib (Velcade)

Following a second resubmission

bortezomib (Velcade®) is accepted for use within NHS Scotland as mono-therapy for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplantation.

Bortezomib, compared to high dose dexamethasone, prolonged time to disease progression and improved survival in patients who had progressive multiple myeloma despite previous treatment with one to three lines of therapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of bortezomib. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland.